Find a Doctor

SW
Areas of Expertise

Steven E. Waggoner

University Hospitals Medical Group Inc
Oncology, Obstetrics and Gynecology
Male
Practicing approx. 37 years

Bio

Steven Waggoner is an Oncologist and an Obstetrics and Gynecologist in Cleveland, Ohio. He has been an author on 46 peer reviewed articles and participated in 19 clinical trials in the past 15 years. He is licensed to treat patients in OH.

Areas of Expertise

Contact

11100 Euclid Ave
Cleveland, OH 44106, US

216-844-3941

Latest Advances

Latest Advance
Study
  • Condition: Advanced cervical cancer
  • Journal: Lancet (London, England)
  • Treatment Used: Bevacizumab plus standard chemotherapy
  • Number of Patients: 331
  • Published —
This phase III trial evaluated the clinical outcomes in terms of overall survival (OS) in patients with metastatic, persistent or recurrent advanced cervical cancer. Researchers administered Bevacizumab plus standard chemotherapy in different combinations as well as without Bevacizumab.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug, Biological
  • Participants: 470
  • Start Date: July 18, 2019
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2/Phase 3
  • Intervention Type: Other, Drug, Biological
  • Participants: 488
  • Start Date: May 12, 2017
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Radiation, Drug, Other
  • Participants: 348
  • Start Date: January 15, 2016
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Other, Radiation, Drug
  • Participants: 360
  • Start Date: April 12, 2010
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)

All Publications
View All

Publication
Conference
  • Sponsor: American Society of Clinical Oncology (ASCO)
  • Event Name: American Society of Clinical Oncology Annual Meeting 2020
  • Published —
A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.
Publication
Study
  • Journal: Gynecologic oncology
  • Published —
Adjusting to the new reality: Evaluation of early practice pattern adaptations to the COVID-19 pandemic.

Contact

11100 Euclid Ave
Cleveland, OH 44106, US

216-844-3941

Affiliations

  • University Hospitals Of Cleveland
  • Uh Geauga Medical Center
  • Uh Geneva Medical Center
  • University Hospitals Ahuja Medical Center
  • Parma Community General Hospital

Credentials

  • Graduate InstitutionUniversity Of Washington School Of Medicine
    1984
  • Licenses
    Obstetrics & Gynecology in OH
  • Board Certifications
    Gynecological Oncology
    Obstetrics/gynecology

Insurance

Contact them to find out if they accept your insurance plan.